Charles River Laboratories (CRL) Tops Q1 EPS by 8c; Boosts Outlook

Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $0.82, $0.08 better than the analyst estimate of $0.74. Revenue for the quarter came in at $299.4 million versus the consensus estimate of $302.08 million.

Charles River Laboratories sees FY2014 EPS of $3.15 - $3.25, versus prior guidance of $.00 - $3.10. Sees sales growth of 9 to 11 percent, from 3 to 5 percent prior.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c